Table 3. Univariate and multivariate COX analyses for early RFS of HCC patients.
| Variables | N=383 | Univariate | Multivariate | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |||
| Gender (female/male) | 46/337 | 0.823 (0.524–1.295) | 0.4 | |||
| Age, years (>50/≤50) | 189/194 | 0.849 (0.642–1.122) | 0.25 | |||
| Smoke (yes/no) | 128/255 | 1.390 (1.041–1.855) | 0.026 | – | – | |
| Drink (yes/no) | 76/307 | 1.259 (0.895–1.771) | 1.259 | |||
| Diabetes (yes/no) | 34/349 | 1.706 (1.112–2.617) | 0.014 | – | – | |
| Cirrhosis (yes/no) | 253/130 | 1.104 (0.815–1.495) | 0.524 | |||
| Ascites (yes/no) | 45/338 | 1.254 (0.824–1.907) | 0.291 | |||
| Tumor diameter, cm (>5/≤5) | 158/225 | 2.121 (1.603–2.807) | <0.001 | 1.526 (1.125–2.071) | 0.007 | |
| Tumor number (multiple/single) | 113/270 | 2.096 (1.576–2.789) | <0.001 | 1.910 (1.432–2.547) | <0.001 | |
| Vascular invasion (yes/no) | 138/245 | 1.849 (1.396–2.449) | <0.001 | – | – | |
| Child-Pugh grade (B/A) | 25/358 | 0.969 (0.563–1.669) | 0.910 | |||
| MELD score (>2/≤2) | 305/78 | 1.215 (0.836–1.766) | 0.307 | |||
| BCLC stage (B-C/0~A) | 209/174 | 1.694 (1.269–2.259) | <0.001 | – | – | |
| Pathological differentiation (poor-moderate/well) | 315/68 | 2.387 (1.503–3.791) | <0.001 | 1.924 (1.199–3.089) | 0.007 | |
| AFP, ng/mL (>400/≤400) | 123/260 | 1.635 (1.227–2.178) | 0.001 | – | – | |
| HBV-DNA, copies/mL (>1,000/≤1,000) | 181/202 | 1.258 (0.952–1.662) | 0.106 | |||
| Fibrinogen, g/mL (>3.52/≤3.52) | 110/273 | 1.882 (1.408–2.517) | <0.001 | 1.449 (1.048–2.002) | 0.025 | |
| NLR (>1.92/≤1.92) | 188/195 | 1.316 (0.995–1.740) | 0.055 | – | – | |
| dNLR (≤2.02/>2.02) | 272/111 | 1.057 (0.770–1.451) | 0.731 | |||
| PLR (>60.28/≤60.28) | 334/49 | 0.852 (0.575–1.264) | 0.426 | |||
| LMR (≤3.84/>3.84) | 184/199 | 1.710 (1.290–2.266) | <0.001 | 1.353 (1.007–1.817) | 0.045 | |
| GPR (>0.33/≤0.33) | 204/179 | 1.548 (1.163–2.061) | 0.003 | – | – | |
| SII (>289.28/≤289.28) | 206/177 | 1.430 (1.078–1.898) | 0.013 | – | – | |
| PNI (≤47.6/>47.6) | 160/223 | 1.477 (1.117–1.953) | 0.006 | – | – | |
| APRI (>0.17/≤0.17) | 254/129 | 1.510 (1.100–2.072) | 0.011 | – | – | |
| ANRI (>9.39/≤9.39) | 249/134 | 1.417 (1.038–1.934) | 0.028 | – | – | |
| ALRI (>25.69/≤25.69) | 152/231 | 1.285 (0.972–1.700) | 0.079 | – | – | |
| ALBI (>−2.79/≤−2.79) | 248/135 | 1.555 (1.141–2.121) | 0.005 | – | – | |
| FIB-4 (>1.46/≤1.46) | 239/144 | 1.252 (0.929–1.686) | 0.140 | |||
| S-index (>0.25/≤0.25) | 172/211 | 1.744 (1.318–2.308) | <0.001 | 1.655 (1.240–2.208) | 0.001 | |
MELD, Model for End-stage Liver Disease; BCLC, Barcelona Clinic Liver Cancer; AFP, α-fetoprotein; HBV, hepatitis B virus; NLR, neutrophil-to-lymphocyte ratio; dNLR, derived neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; GPR, gamma-glutamyl transpeptidase-to-platelet ratio; SII, systemic immune-inflammation index; PNI, prognostic nutritional index; APRI, aspartate transaminase-to-platelet count ratio index; ANRI, aspartate transaminase-to-neutrophil ratio index; ALRI, aspartate transaminase-to-lymphocyte ratio index; ALBI, albumin-bilirubin; FIB-4, fibrosis index based on the four factors; RFS, recurrence-free survival.